AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
AAPL   321.75 (-0.03%)
MSFT   183.03 (+0.11%)
FB   228.04 (-1.67%)
AMZN   2,468.95 (-0.08%)
NVDA   350.76 (-0.42%)
CGC   16.51 (+0.12%)
GE   6.94 (+2.66%)
TSLA   902.35 (+0.47%)
AMD   52.93 (-1.31%)
T   31.01 (+0.23%)
F   5.96 (+1.53%)
BA   154.27 (+1.90%)
Log in

OTCMKTS:NWCINewcardio Stock Price, Forecast & News

$0.0025
0.00 (0.00 %)
(As of 05/21/2020)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.00
Volume1,000 shs
Average Volume5,080 shs
Market Capitalization$102,025.00
P/E RatioN/A
Dividend YieldN/A
Beta3.82
NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NWCI
CUSIPN/A
CIKN/A
Phone510-774-1969

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees10
Market Cap$102,025.00
Next Earnings DateN/A
OptionableNot Optionable

Receive NWCI News and Ratings via Email

Sign-up to receive the latest news and ratings for NWCI and its competitors with MarketBeat's FREE daily newsletter.

Newcardio (OTCMKTS:NWCI) Frequently Asked Questions

How has Newcardio's stock been impacted by COVID-19 (Coronavirus)?

Newcardio's stock was trading at $0.0013 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NWCI shares have increased by 92.3% and is now trading at $0.0025. View which stocks have been most impacted by Coronavirus.

Has Newcardio been receiving favorable news coverage?

News coverage about NWCI stock has trended very positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Newcardio earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNewcardio.

Who are some of Newcardio's key competitors?

What other stocks do shareholders of Newcardio own?

Who are Newcardio's key executives?

Newcardio's management team includes the following people:
  • Dr. Jess Emery Jones M.D., CEO & Director (Age 40)
  • Mr. Greg Sadowski, Chief Operating Officer

What is Newcardio's stock symbol?

Newcardio trades on the OTCMKTS under the ticker symbol "NWCI."

How do I buy shares of Newcardio?

Shares of NWCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Newcardio's stock price today?

One share of NWCI stock can currently be purchased for approximately $0.00.

How big of a company is Newcardio?

Newcardio has a market capitalization of $102,025.00. Newcardio employs 10 workers across the globe.

What is Newcardio's official website?

The official website for Newcardio is www.newcardio.com.

How can I contact Newcardio?

Newcardio's mailing address is 2350 MISSION COLLEGE BLVD. #1175, SANTA CLARA CA, 95054. The company can be reached via phone at 510-774-1969 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.